Gel-One Sales Trends in Anticipation of Changes to the U.S. Price-Disclosure System
First written in FY2023-Q1. 2 of 6 entries say "Restated". Latest entry: FY2024-Q3.
No other company in this theme has enough history to compare yet.
- FY2024-Q3MitigatedAnnual report
「Although single-injection Gel-One in the U.S. is gradually recovering from the impact of the reimbursement system change implemented in July 2022, local sales volumes and our sales declined.」
The impact of the decline in sales resulting from the changes to the insurance reimbursement system showed signs of a gradual recovery. However, the declines in U.S. sales volumes and our revenue have continued. - FY2024-Q2RestatedAnnual report
「U.S. sales volumes and our revenue from Gel-One, a single-injection treatment for improving joint function, declined due to the impact of the changes to the insurance reimbursement system implemented in July 2022.」
The decline in Gel-One's U.S. sales volumes and our revenue resulting from the July 2022 changes to the insurance reimbursement system has continued. - FY2024-Q1RestatedAnnual report
「Local sales volumes and our sales of single-injection Gel-One in the U.S. declined because of the impact of the reimbursement system change implemented in July 2022.」
The decline in Gel-One's U.S. sales volumes and our revenue resulting from the July 2022 changes to the insurance reimbursement system has continued. - FY2023-Q3ReframedAnnual report
「U.S. sales volumes of Gel-One, a single-injection treatment for improving joint function, declined due to the impact of the changes to the insurance reimbursement system implemented in July 2022. Our revenue increased substantially due to the weaker yen.」
The decline in Gel-One's U.S. sales was described as resulting from the impact of changes to the insurance reimbursement system, rather than using the previous wording referring to changes to the price-disclosure system. Although the decline in U.S. sales volumes resulting from the changes has continued, our revenue increased substantially due to the weaker yen. - FY2023-Q2MaterialisedAnnual report
「Local sales volumes of single-injection Gel-One in the U.S. declined because of the impact of the change to the price disclosure system implemented in July 2022. Our sales increased substantially because of the weaker yen.」
The changes to the price-disclosure system, which had been described in FY2023-Q1 as a future market trend, materialized as a decline in Gel-One's U.S. sales volumes from July 2022 onward. - FY2023-Q1First statedAnnual report
「U.S. sales volumes of Gel-One, a single-injection treatment for improving joint function, declined amid market trends ahead of the July 2022 changes to the price-disclosure system, as well as a reaction to the increase in volumes in the same period of the previous year as sales recovered from the impact of COVID-19.」
Market trends ahead of the July 2022 changes to the price-disclosure system were first cited as one factor behind the decline in Gel-One's U.S. sales volumes. The changes themselves were described as scheduled for the future.